F. Lebargy

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study

F. Lebargy, P. Wolkenstein, Mathilde Gisselbrecht et al. · Intensive Care Medicine · 1997 · 205 citations · Full text

Toxic Epidermal Necrolysis, Respiratory Toxicology, Toxicology +6

A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation

Philip Tønnesen, Serena Tonstad, Å. Hjalmarson et al. · Journal of Internal Medicine · 2003 · 143 citations · Full text

Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism.

Bertrand Godeau, A Schaeffer, D. Bachir et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 121 citations

Inflammation, Pulmonary Embolism, Acute Lung Injury +15

Intraepithelial T-Lymphocyte Subsets in the Airways of Normal Subjects and of Patients with Chronic Bronchitis

Michel Fournier, F. Lebargy, François Le Roy Ladurie et al. · American Review of Respiratory Disease · 1989 · 117 citations

Asthma, Inflammatory Lung Disease, Cd4+ Cells +18